Cellistic
Suzanne Snellenberg is currently serving as the VP of Cell Line Development at Cellistic since June 2022. In addition, Suzanne holds the position of Director of Genome Engineering at Ncardia since June 2022. Prior to these roles, Suzanne gained valuable experience in gene editing and discovery services at OXGENE from September 2018 to June 2022. Suzanne's academic background includes a MSc in Biomolecular Sciences from Vrije Universiteit Amsterdam and a BSc from Saxion University of Applied Sciences. Suzanne has also worked as a Postdoctoral Research Scientist at the University of Oxford and as a PhD student at VU University Medical Center.
This person is not in any offices
Cellistic
Launched in April 2022, Cellistic specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. The company’s focus and expertise in iPSC generation and differentiation protocol development makes it well-positioned to partner with innovative cell therapy developers to establish novel advanced therapies. With more than a decade of scientific and technical knowledge transfer from sister company Ncardia, Cellistic is uniquely experienced in designing and optimizing manufacturing procedures for iPSCs that deliver quality products at scale. For more information, visit www.cellistic.com.